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The von Hippel–Lindau (VHL) tumor suppressor gene is a protein interaction hub, controlling
numerous genes implicated in tumor progression. Here we focus on structural aspects of protein
interactions for a list of 35 experimentally veriﬁed protein VHL (pVHL) interactors. Using structural
information and computational analysis we have located three distinct interaction interfaces (A, B,
and C). Interface B is the most versatile, recognizing a reﬁned linear motif present in 17 otherwise
non-related proteins. It has been possible to distinguish compatible and exclusive interactions by
relating pVHL function to interaction interfaces and subcellular localization. A novel hypothesis is
presented regarding the possible function of the N-terminus as an inhibitor of pVHL function.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Von Hippel–Lindau (VHL) syndrome is a dominantly inherited
familial cancer syndrome with variable expression and age-depen-
dent penetrance, characterized by a predisposition to develop var-
ious tumors, including among others hemangioblastomas, clear
cell renal carcinomas and pheochromocytomas. Predisposition to
develop this variety of tumors is linked to germ line inactivation
of the VHL tumor suppressor gene, coding for VHL protein (pVHL).
Pathology development in VHL disease occurs after somatic inacti-
vation of the remaining wild-type allele in a susceptible cell [1].
Certain classes of pVHL mutations confer different site-speciﬁc
risks of cancer, suggesting pVHL to have multiple tissue-speciﬁc
tumor suppressor functions [2]. How pVHL mutations cause differ-
ent disease phenotypes remains incompletely understood.
It is widely accepted that pVHL functions as target recognition
component of the E3 ubiquitin ligase complex targeting the a sub-
units of hypoxia-inducible factors (HIF) for oxygen-dependent pro-
teolytic degradation [3–5]. pVHL inactivation leads to stabilization
of HIF1a and HIF2a and activation of their downstream target
genes implicated in angiogenesis, cell growth, and metabolism,
e.g. vascular endothelial growth factor (VEGF), platelet derived
growth factor (PDGFB), transforming growth factor (TGF) andchemical Societies. Published by E
tto).erythropoietin [6]. However, distinct pVHL-containing complexes
indicate pVHL involvement in different signaling pathways, includ-
ing microtubule dynamics, primary ciliummaintenance, cell prolif-
eration, neuronal apoptosis and extracellular matrix deposition.
Several studies have recently investigated the numerous pVHL
functions, providing insight into pVHL mediated signaling net-
works involved in tumor formation (for recent reviews see
[1,7,8]). Experimental determination of protein interactions pro-
vides growing data about new pVHL partners and, partially, the
protein regions involved. However, a large amount of data remains
to be conﬁrmed.
We address the problem by combining information from exper-
imental data with structural analysis [9–12]. Deﬁning the pVHL
interaction interfaces was the primary goal. As pVHL has more
interaction partners than available surface, some interactions must
be mutually exclusive, while others interact simultaneously [13–
15]. Structural information also offers the possibility to distinguish
domain–domain from peptide–domain interactions [16]. Hypothe-
ses are drawn regarding the expected interaction type in each inter-
face and interaction partners are classiﬁed. Augmented with
functional information we contribute to deﬁne functional sub-net-
works existing in different time and space conditions, adding a dy-
namic component to pVHL function. In contrast to a similar analysis
recently proposed for p53 [17], where the authors made large scale
interaction predictions, here we base our hypotheses on a subset of
experimentally validated interaction data from the literature.lsevier B.V. All rights reserved.
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pVHL interacting proteins and their binding regions (in terms of
amino acid sequence) were extracted from the relevant literature,
with sequences from UniProt [18]. Structures were downloaded
from the PDB [19] where available. Fold recognition was performed
using MANIFOLD [20] to identify a structural template with sufﬁ-
cient sequence similarity in cases with no experimental structure.
FlexServ [21] was used to estimate pVHL ﬂexibility. To map pVHL
evolutionary sequence conservation, 35 closely related sequences
identiﬁed with PSI-BLAST [22] (default parameters) were realigned
with ClustalW [23]. The N-terminal region of pVHL was analyzed to
gain more insight on its function. SPRITZ [24] was used to predict
disorder, the consensus method for secondary structure prediction
[25] and REPETITA [26] to validate the N-terminal repeat. The mul-
tiple sequence alignment was drawn using ESPript [27] and struc-
tures were visualized in PyMol (URL: http://www.pymol.org/).
Regions of pVHL sequence where several proteins interact were
inferred to contain a binding interface. These were mapped on the
pVHL structure considering all residues with high DSSP surface
accessibility [28] and with high structural and functional conserva-
tion scores, derived from Consurf [29] and Crescendo [30], respec-
tively. For each class of interactors, the Pfam [31] and CATH [32]
classiﬁcation codes were compared to search for common domains
or architectures through visual inspection and structural align-
ment. A potential linear motif which could mediate the interaction
with pVHL was searched on the protein sequences using Jalview
[33] starting from the degenerate HIF1a peptide with matches re-
corded and visually inspected. Different peptide deﬁnitions yielded
comparable results (data not shown) and PepSite [34] was used to
score the pVHL surface for candidate interaction motifs. For each
interactor, the GO [35] molecular function and cellular localization
allowed us to determine functions mediated by each interface re-
gion with different space and time patterns.
3. Results and discussion
3.1. Data retrieval
Fig. 1 shows an overview of the sequence features of pVHL.
Information about sequence, domain architecture, structure andFig. 1. pVHL sequence features. Domain architecture and protein sequence alignment
homologous sequences of pVHL are shown in the center. acc: accessibility level from DSS
lines at the bottom of the sequence alignment.function of interactors was collected in a list containing 35 proteins
with experimentally determined pVHL interaction regions (Supple-
mentary data S1). Four molecules (CK1, CK2, GSK3 and NEDD8) are
involved in a post-translational modiﬁcations of speciﬁc amino
acids. The boundaries of pVHL sequence mediating the interaction
has been reﬁned for 26 interactors but remains undeﬁned for ﬁbro-
nectin, COL4A2, HIF1AN, BCL2L11 and VHLAK. The region binding
pVHL has been experimentally determined for 18 proteins and re-
mains unknown for 17 interactors. Structural details are known for
Elongin C (EloC), Elongin B (EloB) and HIF1a which are co-crystal-
lized with pVHL [3–5]. For seven interacting proteins, the pVHL
binding region is a particular domain: p53 DNA binding domain
[36], HuR RRM1 [37], Nur77 hormone receptor [38], Sp1 zinc ﬁn-
gers [39], PRKCD Kinase [40], PRKCZ PB1 [41] and VHLAK KRAB-
A [42] domains. The structure is known only for p53, Sp1 and
PRKCZ PB1 domains, while fold recognition allowed identiﬁcation
of a template with sufﬁcient sequence identity for the others.
The large pVHL binding regions of VDU1/USP33, VDU2/USP20,
Jade-1 and aPKCk contain distinct structural domains separated
by disordered region. HIF1AN and BCL2A11 interact with pVHL
through a linker region. HIF2a and RPB1 interact through a func-
tional motif [43]. The pVHL binding region for ﬁbronectin and
COL4A2 might be located on their N-terminal domain since the
interaction occurs at the intracellular site of the endoplasmic retic-
ulum [6].
3.2. Interface deﬁnition
Fig. 2 summarizes the pVHL structural features with its a- and
b-domains. Comparing the results obtained by Consurf (Fig. 2A)
and Crescendo (Fig. 2B) it is noted that surface regions containing
relevant functional residues are located in two interfaces known to
interact with HIF1a and EloC (1LM8VH and 1LM8CV). In addition a
third interface appears on the back of pVHL. Protein structures fre-
quently interact with various domains using different surface areas
[13]. Mapping the putative protein interacting regions on the pVHL
structure for interactors listed in Supplementary data S1, the
majority of interactions occur in three speciﬁc areas of pVHL that
we deﬁne interfaces A, B and C (see Fig. 2C). No structure is avail-
able for the pVHL N-terminus containing putative phosphorylationof pVHL. The pVHL domains are shown on the top part. Secondary structure and
P (black = high and white = low). The protein-interaction regions are represented as
Fig. 2. pVHL structure overview. (A) Cartoon representations of the pVHL structure
(PDB code 1LM8 chain V) coloured blue (N-terminal) to red (C-terminal). The
structure, shown in standard view (front) and after a 180 rotation around the z-axis
(back), is maintained throughout the following panels. (B) Surface of pVHL projecting
phylogenetic conservation by Consurf. The Consurf prediction is presented with
magenta shading for highly conserved residues and cyan shading showing for variable
residues. (C) Surface of pVHL where Crescendo residues clusters are coloured: lime
green, cluster A; orange, cluster B; yellow, cluster C; red, cluster D; blue, cluster E;
violet, cluster F. (D) Three pVHL interfaces mapped on structure surface of pVHL:
green, interface A; violet, interface B; yellow, interface C. (E) Analysis of pVHL
ﬂexibility of each residue (x-axis) in terms of relative displacement (y-axis, in
Angstroms) in themonomer (continuous line) and in complexwithEloC (dashed line).
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face separately, which are also summarized in Fig. 3.
3.3. Interface A – processing
It has been demonstrated that interaction of EloB and EloC
with pVHL depends on the binding of EloC to a 10-amino acid
a-helical sequence motif xLxxxCxxx[AILV], referred to as the BC
box [44]. pVHL also interacts with Cullin-2 at the speciﬁc Cul2box, located C-terminal to the BC box, forming the E3 ubiquitin
ligase complex responsible for recognition and recruitment of tar-
get proteins to be degraded by the 26S proteasome [45]. Four
proteins, other than EloB/C and Cul2, have been experimentally
determined to interact with the pVHL a-domain through a spe-
ciﬁc domain. The p53, Nur77, HuR and VBP1 interacting regions
overlap with those of EloC. This supports the idea that the pVHL
a-domain mediates domain–domain interactions. The EloC, p53,
HuR and Nur77 domains interacting with VHL have a similar
two-layer sandwich architecture, with different CATH classiﬁca-
tions. Their structures are mainly composed of b-sheets with an
a-helix that might mediate the interaction in analogy to EloC.
The interaction interface between pVHL and EloC is composed
of three pVHL a-helices (H1, H2 and H3) and the H4 helix of EloC,
forming hydrophobic contacts [3]. Flexibility analysis of the pVHL
structure indicates the a-domain as ﬂexible (Fig. 2C) and suggests
a conformational change upon interactor binding as described in
[46].
EloC, p53, HuR, Nur77 and VBP1 are mutually exclusive and
compete for binding to the a-domain (Fig. 3). p53, HuR and
Nur77 are prevalently expressed in the nucleus, and EloC in the
cytoplasm. The a-domain also contains the neddylation site,
K159, which appears to be necessary for ﬁbronectin binding. When
neddylated, pVHL cannot interact with Cul2 and stabilizes ﬁbro-
nectin, showing processing functions depending on localization
and physiological cell status [47].
3.4. Interface B – substrate recognition
The pVHL b-domain (interface B), containing the well-studied
HIF1a binding site, was found to be essential for binding 13 differ-
ent proteins with variations termed B1 and B2. The interaction site
for seven proteins was shown to contain the HIF1a binding site.
The region essential for VDU1 and VDU2 binding overlaps only par-
tially and for HIF1AN and BCL2A11, the speciﬁc pVHL b-domain
interaction site is unknown. Only 10 proteins have experimentally
determined pVHL interacting regions, with a prevalence of
unstructured linkers.
For Sp1 the interaction is known to occur through one of
three Zn ﬁnger domains and pVHL interactions with other
metalloproteins have been hypothesized [48]. Among the listed
Zn ﬁnger domain containing proteins, only the aPKCk binding
region overlaps with its Zn ﬁnger domain. For VDU1, VDU2,
PRKCZ and RPB1 the experimentally determined interacting re-
gion does not contain a Zn ﬁnger. Another domain–domain
interaction has been hypothesized by Zhou et al. [49] which
have shown that the Jade-1 PHD module, structurally similar
to the Zn ﬁnger domain, is most important for VHL-mediated
stabilization. In our list, Jade-1 is the only protein containing a
PHD domain. Another protein Kinase C delta (PRKCD) interacts
with pVHL through the catalytic domain and there is no correla-
tion between degradation of PRKCD and the presence of active
pVHL [40].
Proteins of unknown pVHL interacting region are likely to use
disordered sequence stretches. The HIF1a binding sites, named
ODD domains, are disordered and contain a hydroxylated proline.
It has been demonstrated that RPB1 interacts with pVHL through
a proline [43]. Sharing a conserved motif containing this proline,
it seems interface B mediates interactions occurring between the
pVHL b-domain and different peptides. The known interface B
interactors were systematically searched for linear motifs resem-
bling the HIF1a ODD sequence and structurally validated with Pep-
Site. The results (shown in Fig. 4) point to the presence of a proline
box followed by a hydrophobic box with the consensus pattern
[LIV]xPx(6,9)uxu, where u is prevalently a hydrophobic residue,
in a likely disordered region. This pattern agrees with the location
Fig. 3. Overview of pVHL interactors. Pictures represent pVHL interacting partner in four different cellular compartments: nucleus, cytoplasm, endoplasmic reticulum and
membrane periphery. At the center of each picture there is a cartoon representation of the crystal structure of pVHL (PDB code 1LM8, chain V) highlighting the protein
interface as circles: interface A in cyan, interface B in blue, and interface C in green. When the structure of a pVHL interaction partner is known, it is represented as cartoon,
with their acronym and PDB code. A percentage sequence identity is shown if the structure refers to a homologous protein. Light blue circles are used if the interaction region
is unknown. A red border indicates proteins for which information about pVHL interaction regions exists but it is located in an unstructured region or in domains for which no
structure is available. A grey circle indicates proteins interacting with an unknown pVHL region. KIFAP3 and CK2 interact with the VHL N-terminal sequence which is not
included in the crystal structure. Phosphorylation (red balls) and neddylation sites (yellow ball) are also shown.
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exceptions (PRKCZ, Jade-1 and perhaps VDU1, VDU2) the predicted
motifs ﬁt well into the respective structures. Furthermore, the mo-
tif is present also in the two proteins (HIF1AN and BCL2L11) for
which a speciﬁc b-domain interaction site were not well deﬁned.
Although experimental binding assays will be necessary to verify
the prediction, our results summarize well the plasticity of the
pVHL B interface.
As many interface B interactors result to be mutually exclusive,
the selection of interaction occurs in different ways. Domain–do-
main interactions are more speciﬁc or have higher binding afﬁni-
ties than domain–peptide interactions. The different interactors
have speciﬁc localization, e.g. RPB1 is nuclear while HIF1a is nucle-
ar and cytoplasmic. Another selection criterion may be the time at
which some proteins are expressed with higher concentration. It
appears that pVHL through interface B can bind proteins which will
be ubiquitinylated and then degraded, yet it can also bind other
proteins which will be stabilized, e.g. Jade-1 [49], BCL2L11 [51]
and microtubules (MT) [52]. Interactions with other proteins play
a role in transcriptional regulation [6], e.g. Sp1, HuR, HIF1AN and
perhaps VHLaK for which an interaction pVHL interface remains
unassigned.3.5. Interface C – localization
The back view of pVHL b-domain (Fig. 1) presents two regions
for known interactors. TBP1 interacts with pVHL residues 136–
154 containing a b-sheet and a linker between the VHL a- and b-
domains [53]. It is difﬁcult to predict how TBP1 can interact with
this extended region. Residues 114–138 of pVHL interact with
eEF1A [54] and contain the nuclear export signal (NES),
DxGxxDxxL [55], in a loop between two b-strands forming a polar
interface between pVHL a- and b-domains. Surprisingly, the NES
motif is part of the polar interface partially located in front of the
a-domain. This may be explained by the ﬂexibility of a-domain
which likely changes conformation and increases accessibility for
other proteins. During transport from nucleus to cytoplasm, pVHL
is captured by a nuclear export receptor component. In the cyto-
plasm, TBP1 (component of the 26S proteasome) interacts with
pVHL in complex with EloC, anchoring it to the proteasome where
the ubiquitinylated substrates are degraded [53]. This interface ap-
pears to determine pVHL localization. Interestingly, the areas inter-
acting with TBP1 and eEF1A forming interface C are coded by exon
2 of the VHL gene. Moreover amino acids 114–177 appear to be re-
quired for perinuclear (ER) pVHL localization [56].
Fig. 4. pVHL interface B linear motifs. The putative linear motifs deﬁning pVHL interactions at interface B are shown. (A) Multiple sequence alignment of identiﬁed linear
motifs with the sequence identiﬁer and positions on the left side. The right side contains information on the disorder (Y, yes; N, no; P, partial) and secondary structure (H,
helix; E, extended/beta; and C, coil/loop) and two Pepsite predictions. Pepsite P-values, estimating the probability of achieving a similar result by chance, are complemented
with the presence of the central proline in the predicted motif. Extremely low (bold) and high (italics and underlined) P-values are highlighted. The two regions corresponding
to the Pepsite predictions are drawn above and two motif determinant boxes are drawn below the sequence alignment. In (B) the pVHL structure (PDB code 1LM8, chain V) is
shown oriented as in Fig. 1 with the bound HIF1a peptide in grey spheres. The hydroxylated proline residue is shown in red and the two motif determinant boxes are shown
in darker grey. A typical Pepsite prediction (BCL2L11, Pepsite P-value 0.0001) is shown in (C). Note the similar binding site with proximity to the hydroxylated proline
location.
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pVHL contains several post-translational modiﬁcation sites,
determining its dynamic properties. Reversible pVHL neddylation
distinguishes between HIF-related functions and stabilization of
the extracellular matrix [47]. Together with the localization signals
in interface C this determines to a great extent the precise function
pVHL may be carrying out at any given point in time.
A more elusive pVHL regulatory mechanism is phosphorylation.
Several phosphorylation sites present in or near the pVHL N-termi-
nus are responsible for proper ﬁbronectin deposition [57] and
microtubule dynamics [58]. In addition, the N-terminus is entirely
missing in other mammalian orthologs, suggesting a human spe-
ciﬁc mechanism. Eight tandem repeats with a GxEEx pattern are
contained in the N-terminus (see Fig. 1). REPETITA periodicity anal-ysis strongly suggests that the repeat is a solenoid and covers the
entire pVHL N-terminus, with two degenerate units at the N- and
one at the C-terminal ﬂanks of the GxEEx pattern. All known six-
residue solenoid repeats form b-helix structures [59], where each
repeat corresponds to a short b-strand and a turn typically cen-
tered on a glycine. Whether the pVHL N-terminus can form the
same b-solenoid remains however unclear due to the occurrence
of adjacent charged residues which may cause electrostatic
repulsion.
In any case, the putative phosphorylation sites located in the re-
peat region are likely to cause a conformational switch, creating a
pattern of three charged residues known to be highly correlated
with intrinsic disorder [60]. The serines located close to two pro-
lines (see Fig. 2) have prompted us to use Pepsite to determine
hypothetical pVHL–peptide interactions. Intriguingly, the results
E. Leonardi et al. / FEBS Letters 583 (2009) 3704–3710 3709place the interaction site on interface B in correspondence with the
HIF1a peptide (P-value = 0.024). This opens the possibility that hu-
man pVHL may have evolved a signaling mechanism to deactivate
binding of speciﬁc interactors through phosphorylation and con-
formational rearrangement, e.g. ﬁbronectin [57]. Experiments will
be necessary to verify this hypothesis.
4. Conclusions
We have presented a characterization of pVHL which attempts
to summarize the known experimental interactions and address
them from a structural point of view (see Fig. 3). The modular nat-
ure of pVHL becomes apparent from the subdivision in three inter-
action interfaces corresponding to processing, substrate
recognition and localization. These highlight various protein inter-
action types, namely domain–domain (interface A) and domain–
peptide (interface B), with interface C being less clear. Structural
characterization of the putative interface B interaction peptides
yielded both a complete list of hypothetical interaction motifs
and the intriguing possibility for the pVHL N-terminus to auto-in-
hibit substrate recognition after phosphorylation. Our ﬁndings,
rationalizing pVHL function at the molecular level through exper-
imental data from the literature, can serve as a gold standard for
the analysis of other putative interaction partners. They can be
useful to design and interpret speciﬁc experimental interaction as-
says for the 200 or more remaining putative pVHL interaction part-
ners. Addressing these in different time and space points will
provide the ultimate validation for this complex protein.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2009.10.070.
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